Abstract:Objective To study the relationship between programmed death-1 (PD-1)/programmed death-1 ligand (PD-L1) expressions and serum hepatitis B virus (HBV) DNA levels in chronic hepatitis B (CHB) patients. Methods A total of 137 CHB patients and 10 healthy controls were enrolled in the study. The peripheral blood mononuclear cells (PBMCs) were isolated from fresh blood samples. HBV-specific cytotoxic T lymphocyte (CTL) was expanded in vitro in 64 human leucocyte antigen (HLA)-A2 positive patients. Flow cytometry was used to detect HLA-A2 type,expressions of PD-1/PD-L1 on PBMCs and PD-1 on HBV specific CTL. Interferon gamma (IFN-γ)was measured by commercial enzyme-linked immunosorbent assay (ELISA) kits. PD-1/PD-L1expressions on PBMCs, HBV-specific CTL and IFN-γ level in PBMC culture medium were compared among patients with different baseline HBV DNA levels. Ten hepatitis B e antigen (HBeAg) positive patients were treated with telbivudine for 24 weeks. The above mentioned parameters were determined and compared before and after the antiviral treatment. Independent-samples t test were used to compare means between two groups and one-way A NOVA were used to compare means among multigroups. We used the pearson corretation test to assess corretation significance. Results The PD-1 and PD-L1 expressions on PBMCs in patients with baseline HBV DNA＜3 lg copy/mL, 3-6 lg copy/mL and ＞6 lg copy/mL were all significant higher than those in healthy control group, but no statistical differences were found. PD-1 expressions on HBV-specific CTL in the three CHB patient groups were (69.3±11.2)%, (76.5±9. 1)% and (78.0±11.7)%, respectively. However, PD-1 expression on HBV-specific CTL was higher, while the frequency of HBV-specific CTL cells was lower in HBV DNA ＞6 lg copy/mL group compared to HBV DNA＜3 lg copy/mL group. The above parameters, including expressions of PD-1 and PD-L1, the frequency of HBV-specific CTL and its PD-1 expression were not significantly different between HBeAg-positive group and HBeAg-negative group. Compared with baseline, PD-1 and PD-L1 expression decreased obviously accompanying with increase of HBV-specific CTL cells frequency and IFN-γ level after 12 weeks and 24 weeks of telbivudine treatment. Conclusions PD-1 expression on HBV-specific CTL correlates with serum HBV DNA level, but not HBeAg status in CHB patients. Suppression of HBV replication can reduce PD-1/PD-L1 expressions and partially restore HBV specific CTL function.

PD-L1 upregulation by IFN-α/γ-mediated Stat1 suppresses anti-HBV T cell response

Increasing LAG-3 Expression Suppresses T-cell Function in Chronic Hepatitis B

Increasing LAG-3 expression suppresses T-cell function in chronic hepatitis B: A balance between immunity strength and liver injury extent.

JAK/STAT Signaling is Involved in IL-35-induced Inhibition of Hepatitis B Virus Antigen-Specific Cytotoxic T Cell Exhaustion in Chronic Hepatitis B

PD-1 Upregulation is Associated with HBV-specific T Cell Dysfunction in Chronic Hepatitis B Patients.

Intrahepatic PD-1/PD-L1 up-regulation closely correlates with inflammation and virus replication in patients with chronic HBV infection.

HBV Inhibits LPS-induced NLRP3 Inflammasome Activation and IL-1β Production Via Suppressing the NF-κB Pathway and ROS Production.

Dynamic Programmed Death 1 Expression by Virus-Specific CD8 T Cells Correlates with the Outcome of Acute Hepatitis B

Type 1 interferon-induced IL-7 maintains CD8+ T-cell responses and homeostasis by suppressing PD-1 expression in viral hepatitis

MicroRNA-138 Regulates T-Cell Function by Targeting PD-1 in Patients with Hepatitis B Virus-Related Liver Diseases

297 SUSTAINED OVEREXPRESSION OF PROGRAMMED DEATH-1 RECEPTOR ON CD8+T CELLS WAS ACTIVELY INVOLVED IN THE LETHAL EXACERBATION IN PATIENTS WITH HBV-RELATED ACUTE-ON-CHRONIC LIVER FAILURE

Longitudinal Fluctuations in PD1 and PD-L1 Expression in Association with Changes in Anti-Viral Immune Response in Chronic Hepatitis B

Inhibition of STAT1 Methylation is Involved in the Resistance of Hepatitis B Virus to Interferon Alpha

PD-1/PD-L signaling pathway in chronic hepatitis B

Correlation of programmed death-1 and programmed death-1 ligand expressions with hepatitis B virus DNA in chronic hepatitis B virus infection patients

Rapid downregulation of programmed death-1 and interferon-γ-inducible protein-10 expression is associated with favourable outcome during antiviral treatment of chronic hepatitis B.

PD-L1 expression in hepatocytes and the regulation by interferon-α and hepatitis B virus

Inhibition of viral replication downregulates CD4 +CD25 high regulatory T cells and programmed death-ligand 1 in chronic hepatitis B

Simultaneous or prior activation of intrahepatic type I interferon signaling leads to hepatitis B virus persistence in a mouse model

Programmed Death 1 and Programmed Death Ligand 1 Expressions in Patients with Chronic Hepatitis B

Altered TNF-α and IFN-γ levels associated with PD1 but not TNFA polymorphisms in patients with chronic HBV infection